Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Link

Showing results (281-290 of 328) with videos related to

Pageof 33
Sort By:
Nature Communications|August 8, 2024
Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulationMatthew E Stokes, Kerstin Wenzl, C Chris Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyHervé Ghesquieres, Susan L Slager, Fabrice Jardin, et al.
British Journal of Haematology|December 22, 2018
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphomaBrian T Hill, Loretta Nastoupil, Allison M Winter, et al.
Blood|April 3, 2015
The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphomaRebecca L Boddicker, N Sertac Kip, Xiaoming Xing, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCLKerstin Wenzl, Matt Stokes, Joseph P Novak, et al.
Blood Cancer Journal|June 20, 2024
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCLKerstin Wenzl, Matthew E Stokes, Joseph P Novak, et al.
Blood|August 11, 2018
Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with <i>DUSP22</i> rearrangementsRebecca A Luchtel, Surendra Dasari, Naoki Oishi, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2025
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell LymphomaLoretta J Nastoupil, Clark R Andersen, Amy Ayers, et al.
Blood|May 19, 2019
Recurrent <i>MSC</i> <sup>E116K</sup> mutations in ALK-negative anaplastic large cell lymphomaRebecca A Luchtel, Michael T Zimmermann, Guangzhen Hu, et al.
Eclinicalmedicine|April 18, 2024
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatmentLuca Arcaini, Côme Bommier, Juan Pablo Alderuccio, et al.
Pageof 33

Showing results (281-290 of 328) with videos related to

Sort By:
Pageof 33
Nature Communications|August 8, 2024
Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulationMatthew E Stokes, Kerstin Wenzl, C Chris Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyHervé Ghesquieres, Susan L Slager, Fabrice Jardin, et al.
British Journal of Haematology|December 22, 2018
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphomaBrian T Hill, Loretta Nastoupil, Allison M Winter, et al.
Blood|April 3, 2015
The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphomaRebecca L Boddicker, N Sertac Kip, Xiaoming Xing, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCLKerstin Wenzl, Matt Stokes, Joseph P Novak, et al.
Blood Cancer Journal|June 20, 2024
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCLKerstin Wenzl, Matthew E Stokes, Joseph P Novak, et al.
Blood|August 11, 2018
Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with <i>DUSP22</i> rearrangementsRebecca A Luchtel, Surendra Dasari, Naoki Oishi, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2025
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell LymphomaLoretta J Nastoupil, Clark R Andersen, Amy Ayers, et al.
Blood|May 19, 2019
Recurrent <i>MSC</i> <sup>E116K</sup> mutations in ALK-negative anaplastic large cell lymphomaRebecca A Luchtel, Michael T Zimmermann, Guangzhen Hu, et al.
Eclinicalmedicine|April 18, 2024
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatmentLuca Arcaini, Côme Bommier, Juan Pablo Alderuccio, et al.
Pageof 33